Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 13/20 | 0.53 |
| ▸ | BCHE | P06276 | 13/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22366416 | 0.98 | BCHE (0.50) | BCHEACHE | |
| Bromide SCHEMBL22366540 | 0.85 | ADRA1D (0.44) | — | |
| SCHEMBL61954 | 0.82 | HPGD (0.53) | — | |
| Bromide SCHEMBL22366474 | 0.81 | RPS6KA2 (0.51) | — | |
| Bromide SCHEMBL22366451 | 0.79 | GLS (0.44) | — | |
| Bromide SCHEMBL22366418 | 0.79 | MAOB (0.46) | — | |
| Bromide SCHEMBL22366410 | 0.79 | CHKA (0.49) | — | |
| Hydrochloric Acid SCHEMBL22366543 | 0.76 | GLS (0.44) | ACHE | |
| Bromide SCHEMBL7049876 | 0.75 | CHRM2 (0.53) | — | |
| Bromide SCHEMBL22366400 | 0.75 | HPGD (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339567-A1 | SUBSTITUTED IMIDAZOPYRIDINE AMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2020-10-29 | — | — | US | disclosed |
| EP-3700903-A1 | SUBSTITUTED IMIDAZOPYRIDINE AMIDES AND USE THEREOF | Bayer Aktiengesellschaft (DE) | 2020-09-02 | — | — | EP | disclosed |
| CN-111225917-A | Substituted imidazopyridine amides and uses thereof | 拜耳股份公司 | 2020-06-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339567-A1 | SUBSTITUTED IMIDAZOPYRIDINE AMIDES AND USE THEREOF | GOT2, ABAT, OAT | ACHE 111/4885BCHE 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.